Mural Oncology(MURA) Stock Price Today

English
中文繁體
中文简体

Dark
Light

Open Account

Download

US Stock MarketDetailed Quotes

MURA Mural Oncology

Watchlist

1.540
-2.290-59.79%

Trading Mar 25 10:05 ET

26.53MMarket Cap-0.20P/E (TTM)

Intraday

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Sector Update: Health Care Stocks Steady Premarket Tuesday
MT Newswires58minutes ago
Wall Street Calms After Monday's Rise, Driving Narrow Premarket Gains for US Equity Futures
MT Newswires08:58 ET
Mural Oncology Shares Are Trading Lower After the Company Announced It Will Discontinue Its Final Analysis of Nemvaleukin in Combination With KEYTRUDA and Will Cease Further Development. Jones Trading Downgraded the Stock From Buy to Hold.
Benzinga08:50 ET
Express News | Mural Oncology Shares Are Trading Lower After the Company Announced It Will Discontinue Its Final Analysis of Nemvaleukin in Combination With KEYTRUDA and Will Cease Further Development. Jones Trading Downgraded the Stock From Buy to Hold
Benzinga08:50 ET
Mural Oncology Analyst Ratings
Benzinga08:31 ET · Ratings
Tenon TNON FDA Clearance; Mural Oncology MURA Cease Development
BioPharmCatalyst08:30 ET

Comments

Hellohellohellohello

1 hour ago

$Mural Oncology (MURA.US)$ filed chapter 11?

Trytosaveabit

3 hours ago

update

$Mural Oncology (MURA.US)$ Mural Oncology Provides Update on Phase 3 ARTISTRY-7 Trial of Nemvaleukin in Combination with KEYTRUDA® (pembrolizumab) in Patients with Platinum-Resistant Ovarian Cancer
3 MINUTES AGO, 6:30 AM EDT
VIA GLOBENEWSWIRE
Based on overall survival data observed in interim analysis in platinum-resistant ovarian cancer, Mural will not progress trial to final analysis
Continued demonstration of favorable tolerability profile generally consistent with previously reported d...

Jaguar8

Jan 10 05:01

NEWS

$Mural Oncology (MURA.US)$
Mural Oncology Highlights Pipeline Progress and Anticipated 2025 Catalysts
Thursday, 9th January at 4:00 pm
Readouts for two late-stage, potentially registrational trials of nemvaleukin alfa expected in late Q1/early Q2 2025 for platinum-resistant ovarian cancer and Q2 2025 for mucosal melanoma
Preliminary data readouts for less-frequent intravenous dosing of nemvaleukin in patients with cutaneous melanoma expected in 1H 2025 for monotherapy, with patient enrollment...

Teddy123

Nov 21, 2024 07:49

Mural Oncology Announces Publication Highlighting Promising Clinical Antitumor Activity Shown in its ARTISTRY-1 Clinical Trial of Nemvaleukin, its Lead Engineered Fusion Protein, in the Journal for Im

$Mural Oncology (MURA.US)$
Mural Oncology's Cancer Drug Shows 33% Response Rate in Melanoma Trial Data | MURA Stock News

Jaguar8

Nov 21, 2024 05:19

NEWS

$Mural Oncology (MURA.US)$
Mural Oncology Announces Publication Highlighting Promising Clinical Antitumor Activity Shown in its ARTISTRY-1 Clinical Trial of Nemvaleukin, its Lead Engineered Fusion Protein, in the Journal for ImmunoTherapy of Cancer
Mural Oncology has published promising clinical data from its completed ARTISTRY-1 phase 1/2 trial of nemvaleukin, showing positive antitumor activity in both monotherapy and combination therapy with pembrolizumab.
The trial, involving 286 patient...

Market Insights

Symbol Mini Chart % Chg

Petroleo Brasileiro SA Petrobras

Unlock the Full List